/ 2 items

#ACAD↓

ACAD/ 02/02/2026 · 5:18 PM

Acadia Pharmaceuticals Faces EU Setback for Rett Syndrome Drug Trofinetide

Acadia Pharmaceuticals (ACAD) receives negative CHMP vote for trofinetide EU approval despite 1,000+ patients using treatment globally. Company plans re-examination request.

ACAD/ 09/24/2025 · 7:52 AM

Acadia Pharmaceuticals Shares Fall as ACP-101 Trial Misses Primary Endpoint

Acadia's experimental drug, ACP-101 (intranasal carbetocin), designed to treat extreme hunger (hyperphagia) in Prader-Willi syndrome patients, did not meet its main goal in the recent Phase 3 trial.